Loading…
DIA Europe 2019 has ended
Back To Schedule
Wednesday, February 6 • 09:15 - 10:15
#DMD9: Brexit and the European Network: 1,5 months to go! Where Do We Stand?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session

The session will discuss the challenges and solutions identified within the EU Regulatory Network on how to carry forward after the UK is no longer an official member of the European Union. It will discuss the tactical solutions put in place to continue operating without disturbance and also give advice to the industry on the expectations on them.

Chair

Christa Wirthumer-Hoche, PhD

Speaker

Panel Discussion
Kora H Doorduyn-van der Stoep, MSc, RPh

Panel Discussion
Anthony Humphreys, MPharm

Panel Discussion
Hugo Hurts

Panel Discussion
Nick Meade, MSc

Panel Discussion
Lorraine Nolan, PhD

Panel Discussion
Aimad Torqui, MSc


Speakers
avatar for Hugo Hurts

Hugo Hurts

Chair HMA Task Force; Executive Director, Medicines Evaluation Board (MEB)
NM

Nick Meade

Director of Policy, Genetic Alliance UK
Nick Meade leads the policy work of Genetic Alliance UK. The organisation works on behalf of more than 230 patient organisation member groups, aiming to improve outcomes for everyone affected by genetic, rare and undiagnosed conditions through evidence-based influencing and campaigning... Read More →
avatar for Christa Wirthumer-Hoche

Christa Wirthumer-Hoche

Chair, EMA Management Board, Head, Austrian Medicines and Medical Devices Agency
Christa Wirthumer-Hoche studied biochemistry TU Vienna, doctoral thesis at Medical Physiology. Starting at the AT Nat. Inst. for Quality Control of Drugs - quality assessment, Head of Regulatory Affairs in the Ministry of Health, Now Head of the Austrian Medicines and Medical Devices... Read More →
avatar for Anthony Humphreys

Anthony Humphreys

Head of Scientific Committees Regulatory Science Strategy, European Medicines Agency (EMA)
He is the Head of Scientific Committees Regulatory Science Strategy Division (SciRS). He is responsible for providing leadership in the Agency in the areas of Scientific Committees Coordination and Regulatory Science Strategy in support of delivering the EMRN 2020 Strategy. He chairs... Read More →
avatar for Lorraine Nolan

Lorraine Nolan

Chief Executive, Health Products Regulatory Authority , Ireland
Dr Nolan joined the HPRA in 2001 and since that time has held a number of different roles at senior level within the organisation across a range of areas including inspection and authorisation of human medicines, medical devices, cosmetics and controlled substances. Prior to assuming... Read More →
avatar for Kora Doorduyn-van der Stoep

Kora Doorduyn-van der Stoep

Vice-Chairperson CMDh (NL) and CMDh Member/Senior Policy Adviser, Medicines Evaluation Board, Netherlands
Her current position (since 2009) is CMDh member (EU-representative)/Policy adviser of the department Policy, Governance and Regulatory Affairs. Since May 2009 she is acting as Member and official representative in the CMDh on behalf of the MEB. She is member of several working parties... Read More →
AT

Aimad Torqui

Director Global Regulatory Policy, MSD
Aimad Torqui is Director of Global Regulatory Policy at MSD. Previous employment includes Medicines Evaluation Board and Novartis Vaccines. He has worked with governments, regulators, trade bodies and other external stakeholders to shape robust science-based regulatory policy.

Wednesday February 6, 2019 09:15 - 10:15 CET
F1 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  DIAmond Sessions, Session
  • Featured Topics Regulatory Science
  • Tags Session